News

Madrigal Pharmaceuticals has secured worldwide rights to develop ARO-PNPLA3, an experimental treatment created by Arrowhead Pharmaceuticals for people with metabolic dysfunction-associated steatohepatitis (MASH),…

Children with biliary atresia who had evidence of active cytomegalovirus (CMV) infection involving bile duct cells in the liver had signs of more severe…

May is Hepatitis Awareness Month, and advocates are working to spread the word about viral hepatitis — a group of infections that cause liver…

Twice-daily treatment with volixibat, Mirum Pharmaceuticals’ oral investigational therapy for primary sclerosing cholangitis (PSC) significantly outperformed a placebo in reducing moderate to severe…

In a rat model of segmental cholestasis, a condition in which bile flow is blocked in certain areas of the liver, treatment with pioglitazone…

A once-monthly investigational therapy for metabolic dysfunction-associated steatohepatitis (MASH), called efimosfermin, has earned two new regulatory designations — one in the U.S. and the other…

Due to limited access to genetic testing, a young girl with Alagille syndrome in Indonesia was misdiagnosed in infancy with biliary atresia —…

The U.S. Food and Drug Administration (FDA) has accepted and placed under priority review an application seeking approval of bepirovirsen, GlaxoSmithKline (GSK)’s investigational therapy,…

Adults with primary biliary cholangitis (PBC) who have less elevated blood levels of the liver enzyme alkaline phosphatase (ALP), a marker of liver damage, at…

Researchers have developed a new mouse model of progressive familial intrahepatic cholestasis type 3 (PFIC3) that more closely mimics key features of the disease…